Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)

A fibroblast growth factor receptor that regulates CHONDROCYTE growth and CELL DIFFERENTIATION. Mutations in the gene for fibroblast growth factor receptor 3 have been associated with ACHONDROPLASIA; THANATOPHORIC DYSPLASIA and NEOPLASTIC CELL TRANSFORMATION.

Also Known As:

Networked: 330 relevant articles (2 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Zwarthoff, Ellen C: 12 articles (07/2013 - 12/2002)
2.	van Rhijn, Bas W G: 8 articles (08/2014 - 12/2002)
3.	Legeai-Mallet, Laurence: 8 articles (12/2012 - 07/2006)
4.	Radvanyi, François: 7 articles (10/2013 - 01/2003)
5.	Hristova, Kalina: 7 articles (01/2013 - 02/2006)
6.	Munnich, Arnold: 7 articles (12/2012 - 07/2006)
7.	Stewart, A Keith: 6 articles (10/2015 - 07/2003)
8.	van der Kwast, Theo H: 6 articles (08/2014 - 01/2003)
9.	Trudel, Suzanne: 6 articles (11/2006 - 03/2004)
10.	Krejci, Pavel: 5 articles (01/2016 - 06/2009)

Related Diseases

1.	Achondroplasia 06/01/2002 - "[corrected] To investigate the mutation at the transmembrane domain of fibroblast growth factor receptor 3 (FGFR3) nucleotide 1138 site for identifying the major pathologic mechanism of achondroplasia (ACH) and to evaluate the efficacy of denaturing gradient gel electrophoresis(DGGE) method for screening the point mutations. " 11/01/1998 - "Recent studies of the fibroblast growth factor receptor 3 (FGFR3) gene have established that achondroplasia and hypochondroplasia are allelic disorders of different mutations. " 01/02/1995 - "Recent studies mapped the achondroplasia gene on chromosome region 4p16.3 and identified a common mutation in the gene encoding the fibroblast growth factor receptor 3 (FGFR3). " 03/01/2015 - "The most common achondroplasia mutation, p.Gly380Arg in fibroblast growth factor receptor 3 (FGFR3), was detected in both patients. " 01/01/2014 - "Achondroplasia is caused, in virtually all of the cases, by a G380R mutation in fibroblast growth factor receptor 3 (FGFR3). "
2.	Carcinoma (Carcinomatosis) 05/15/2003 - "Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome." 01/01/2016 - "Enhanced Expression of Fibroblast Growth Factor Receptor 3 IIIc Promotes Human Esophageal Carcinoma Cell Proliferation." 05/01/2015 - "Urothelial carcinoma of the bladder in patients aged 30 years or younger: clinicopathological analysis and expression of fibroblast growth factor receptor 3 (FGFR3) of 45 cases." 01/01/2014 - "Alterations in fibroblast growth factor receptor 3 (FGFR3) have been implicated in the pathogenesis of urothelial carcinoma. " 07/01/2011 - "The human fibroblast growth factor receptor 3 (FGFR3) gene is frequently mutated in superficial urothelial cell carcinoma (UCC). "
3.	Urinary Bladder Neoplasms (Bladder Cancer) 09/01/2005 - "Previous gene expression studies have shown that fibroblast growth factor receptor 3 (FGFR3) is overexpressed in early stages of bladder cancer. " 04/09/2015 - "Fibroblast Growth Factor Receptor 3 (FGF-R3): A Promising Therapeutic Target for the Treatment of Bladder Cancer." 07/01/2013 - "Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer." 05/01/2013 - "Several genetic changes may occur in bladder cancer, but activating mutations in the fibroblast growth factor receptor 3 (FGFR3) genes are the most common and most specific genetic abnormality in bladder cancer. " 05/01/2013 - "Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer."
4.	Thanatophoric Dysplasia (Dwarfism, Thanatophoric) 09/01/2013 - "Thanatophoric dysplasia (TD) and hypochondroplasia are both caused by FGFR3 (fibroblast growth factor receptor 3) gene mutations. " 05/01/2012 - "Fetal thanatophoric dysplasia is a lethal skeletal dysplasia due to mutation of fibroblast growth factor receptor 3 gene. " 01/01/2010 - "Nucleotidic sequence using QF-PCR on exons 7,10, 15, 19 of the fibroblast growth factor receptor 3 (FGFR3) demonstrated a 742 C>T (R248C) mutation, which resulted in an Arg248Cys substitution in heterozygous state, leading to a prenatal diagnosis of thanatophoric dysplasia type I. The early diagnosis of this lethal form of skeletal dysplasia directed the prenatal counseling and allowed appropriate obstetric management. " 06/01/2009 - "Thanatophoric dysplasia is a lethal chondrodysplasia caused by heterozygous fibroblast growth factor receptor 3 (FGFR3) missense mutations. " 06/01/2007 - "Recurrent missense fibroblast growth factor receptor 3 (FGFR3) mutations have been ascribed to skeletal dysplasias of variable severity including the lethal neonatal thanatophoric dysplasia types I (TDI) and II (TDII). "
5.	Multiple Myeloma 03/01/2004 - "Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma." 01/01/2014 - "The t(4; 14) translocation leads to the simultaneous overexpression of two genes, FGFR3 (fibroblast growth factor receptor 3) and MMSET (multiple myeloma SET domain), both of which have potential oncogenic activity. " 09/01/2011 - "Fibroblast growth factor receptor 3 (FGFR3) is up-regulated as a result of the t(4;14)(p16;q32) translocation that occurs in up to 20% of multiple myeloma (MM) patients. " 01/01/2011 - "The ectopically expressed fibroblast growth factor receptor 3 (FGFR3) and its constitutively active mutations have been detected in patients with multiple myeloma (MM). " 07/15/2010 - "Reciprocal IGH/14q32 translocations are detectable in 55-70% of patients with plasma cell myeloma; e.g., the adverse t(4;14)(p16;q32) fusing the IGH and FGFR3 genes (immunoglobulin heavy chain/fibroblast growth factor receptor 3). "

Related Drugs and Biologics

1.	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)
2.	Phosphotransferases (Kinase)
3.	Muenke Syndrome
4.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
5.	Messenger RNA (mRNA)
6.	Antibodies
7.	Telomerase (Telomerase Reverse Transcriptase)
8.	MicroRNAs (MicroRNA)
9.	Catalytic RNA (Ribozymes)
10.	nuclear matrix protein 22

Related Therapies and Procedures

1.	Drug Repositioning
2.	Heterologous Transplantation (Xenotransplantation)